期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 425, 期 2, 页码 117-120出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0014-2999(01)01158-X
关键词
Ca2+; doxorubicin L-carnitine cardioprotection cardiotoxicity cardiomyocyte
Doxorubicin is a highly effective anticancer chemotherapeutic agent that produces a dose-dependent cardiomyopathy that limits its clinical usefulness. We investigated the acute effects of doxorubicin on diastolic free Ca2+. concentrations ([Ca2+]) and the cardioprotective action Of L-carnitine in isolated cardiomyocytes loaded with fura-2/AM (acetoxymethyl ester). Exposure to 10(-6)-10(-4) M doxorubicin induced an elevation of diastolic calcium concentration ([Ca2+]) that was concentration dependent. Nitrendipine failed to prevent the doxorubicin-induced elevation of [Ca2+]. Incubation with L-carnitine (10(-8) to 10(-6) M) did not modify [Ca2+]. Pretreatment of cardiomyocytes with L-carnitine 10(-8)-10(-7) M did not prevent the doxorubicin effect on [Ca2+]. However, L-Carnitine 10(-6) M fully inhibited the increase in [Ca2+] induced by this anthracycline derivative. These results indicate that acute exposure to doxorubicin impairs intracellular Ca2+ handling and that L-carnitine exerts a cardioprotective effect, in part by preventing the doxorubicin-induced increase in diastolic Ca2+ concentration. (C) 2001 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据